BALAPIRAVIR
Balapiravir is a small molecule pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
2 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hepatitis c | D006526 | — | B19.2 | — | 1 | — | — | — | 1 |
| Chronic hepatitis c | D019698 | EFO_0004220 | B18.2 | — | 1 | — | — | — | 1 |
| Hepatitis | D006505 | HP_0012115 | K75.9 | — | 1 | — | — | — | 1 |
| Hepatitis a | D006506 | EFO_0007305 | B15 | — | 1 | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | BALAPIRAVIR |
| INN | balapiravir |
| Description | Balapiravir (R-1626, Ro4588161) is an experimental antiviral drug which acts as a polymerase inhibitor. There were efforts to develop it as a potential treatment for hepatitis C, and it was subsequently also studied in Dengue fever, but was not found to be useful. Lower doses failed to produce measurable reductions in viral load, while higher doses produced serious side effects such as lymphopenia which precluded further development of the drug. Subsequent research found that excess cytokine production triggered by Dengue virus infection prevented the conversion of the balapiravir prodrug to its active form, thereby blocking the activity of the drug.
|
| Classification | Small molecule |
| Drug class | antivirals: treatments of SARS-CoV-2 infection, inhibiting viral RNA replication |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CC(C)C(=O)OC[C@@]1(N=[N+]=[N-])O[C@@H](n2ccc(N)nc2=O)[C@H](OC(=O)C(C)C)[C@@H]1OC(=O)C(C)C |
Identifiers
| PDB | — |
| CAS-ID | 690270-29-2 |
| RxCUI | — |
| ChEMBL ID | CHEMBL550936 |
| ChEBI ID | — |
| PubChem CID | 11691726 |
| DrugBank | — |
| UNII ID | VOT0LP7I9K (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 263 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use